Ruthenium Based Anticancer Compounds and Their Importance
Rahul Kanaoujiya, Mukta Singh, Jyoti Singh, Shekhar Srivastava
Abstract
Ruthenium has numerous properties, while platinumbased compounds , have served as very successful anti-cancer drugs, they have several limitations including their side effects as well as ineffectiveness against certain types of cancer. Though most ruthenium complexes are only in the beginning stages of the approval process for anti-cancer drugs, many of their properties may give them advantages over many platinum-based drugs now in use. Herein, the recent literature is reviewed critically to ascertain likely mechanisms of action of Ru-based anticancer drugs, with the emphasis on their reactions with biological media. This diversity of modes of action of Ru anticancer drugs is also likely to enhance their anticancer activities and to reduce the potential for them to develop tumour resistance. Ruthenium have several chemical properties, these chemical properties are very useful for anticancer drug design. Ruthenium compounds have various type of advantages as metallodrugs because of lower toxicity emerging as a new and different therapeutic alternatives to platinum drugs. Ruthenium has unique properties which make it particularly useful in drug design. In this overall review we discuss ruthenium from a clinical stance and anticancer drug design uses of ruthenium-based compounds.